Opinion|Videos|December 21, 2023
Update from the POLARIX Study on Pola-R-CHP in DLBCL
Medical oncologists discuss recent data from the POLARIX study investigating polatuzumab vedotin plus R-CHP in patients with diffuse large B-cell lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
How Disease Burden Shapes First-Line RCC Treatment Selection
4
Rivoceranib Plus Camrelizumab Resubmitted to FDA in Frontline HCC
5